BBIXF:OTC-Bonus BioGroup Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.05

Change

+0.02 (+42.86)%

Market Cap

USD 0.07B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 42.38B
UCBJY UCB SA ADR

+1.02 (+1.04%)

USD 37.09B
UCBJF UCB SA

-5.05 (-2.58%)

USD 36.78B
GNMSF Genmab A/S

+5.08 (+2.72%)

USD 12.54B
WXIBF WuXi Biologics

N/A

USD 11.13B
WXXWY WuXi Biologics (Cayman) Inc

-0.06 (-1.08%)

USD 11.13B
IVBIY IVBIY

N/A

USD 7.80B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.33B
ZLDPF Zealand Pharma A/S

N/A

USD 7.23B
AKESF Akeso, Inc.

+0.51 (+6.36%)

USD 7.00B

ETFs Containing BBIXF

QCLN:F 7.49 % 0.00 %

N/A

N/A
QCLN:XETRA 7.49 % 0.00 %

N/A

N/A
QCLN First Trust NASDAQ® Clea.. 6.64 % 0.60 %

+0.11 (+0%)

USD 0.55B
QCLU:LSE First Trust Nasdaq® Clea.. 6.20 % 0.00 %

-0.16 (0%)

USD 0.01B
QCLN:LSE First Trust Nasdaq Clean .. 6.12 % 0.00 %

-11.55 (0%)

USD 0.01B
DRUP:F 1.83 % 0.00 %

N/A

N/A
MIDF 1.54 % 0.00 %

N/A

N/A
IXN iShares Global Tech ETF 0.00 % 0.46 %

-0.04 (0%)

N/A
XSD SPDR® S&P Semiconductor .. 0.00 % 0.35 %

+0.71 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 150.00% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.00% 92% A 96% N/A
Trailing 12 Months  
Capital Gain 66.67% 82% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.67% 82% B 87% B+
Trailing 5 Years  
Capital Gain -61.12% 64% D 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.12% 63% D 32% F
Average Annual (5 Year Horizon)  
Capital Gain 633.07% 89% A- 94% A
Dividend Return 633.07% 89% A- 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,849.81% 12% F 6% D-
Risk Adjusted Return 22.21% 76% C+ 57% F
Market Capitalization 0.07B 73% C 55% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector